[Invasive candidiasis in the critically ill, patient non-neutropenic].
Invasive candidiasis can occur in immunosuppressed patients as well as in critically ill, non-immunocompromised patients and is associated with high mortality (20-40 %). Intestinal Candida colonisation is an important source for invasive candidiasis. Risk factors for the development of invasive candidiasis include presence of an intravascular device, organ dysfunction, impaired mucosal or skin barrier function, therapy with antacids or corticosteroids, prolonged stay at the ICU, total parenteral nutrition and prolonged antibiotic therapy. Among patients with invasive candidiasis, antifungal treatment should be started without delay. Antifungal prophylaxis is currently not recommended in critically ill, non-immunocompromised patients.
Schwetz
Ines
I
Infektiologie und Klinische Abteilung für Pulmonologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Osterreich.
Domej
Wolfgang
W
Krause
Robert
R
D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy; D016638:Critical Illness; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007362:Intensive Care Units; D007413:Intestinal Mucosa / Q000382:microbiology; D009503:Neutropenia / Q000175:diagnosis / Q000188:drug therapy; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy; D012307:Risk Factors
D000935:Antifungal Agents